Search results
Showing 3136 to 3150 of 9065 results
Good practice guidance – Integrated process statement (PMG12)
This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)
This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs
Evidence summaries: new medicines – Interim process statement (PMG1)
This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs
Methods for the development of NICE public health guidance (third edition) (PMG4)
This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance
Home Implementing NICE guidance...
Home Implementing NICE guidance Social care...
Download (PDF) Treatment pathways We have produced treatment pathways bringing together NICE
Appraisal is the process of determining which records have continuing business or historical value from those which have no further value and should be disposed of appropriately.
Learn more about what NICE content is available for reuse by checking our information asset register.
Our projects and partnerships help us anticipate and adapt to policy developments, including changes in health and social care delivery.
The NICE board sets out our strategic priorities and policies.
This indicator covers the percentage of patients with diabetes, on the register, who have a record of retinal screening in the preceding 12 month. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM98.
This indicator covers the percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM95.
Agenda and papers of the NICE public board meeting on 18 March 2026
GPs help to bring a primary care perspective to the guidance that we produce.